Holen Sie sich die Stockscreener-App
29.52
0.54%
0.16
Handel nachbörslich:
29.71
0.19
+0.64%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Will Ultragenyx Pharmaceutical Inc. Recover After Recent Decline2025 Fundamental Recap & Daily Profit Maximizing Trade Tips - newsyoung.net
Ultragenyx starts FDA marketing application process for its gene therapy - MSN
Machine Learning Models Forecast Ultragenyx Pharmaceutical Inc. UptickBear Alert & Reliable Breakout Forecasts - kangso.co.kr
Ultragenyx Initiates Rolling Submission of Biologics License Application to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia - MarketScreener
Ultragenyx Initiates Rolling BLA Submission for DTX401 Gene Therapy - AInvest
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa Treatment. - AInvest
Ultragenyx initiates rolling submission of BLA to U.S. FDA for DTX401 - TipRanks
Chartists See Breakout Potential in Ultragenyx Pharmaceutical Inc.July 2025 Weekly Recap & AI Enhanced Trade Execution Alerts - 선데이타임즈
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewswire
Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy - TradingView
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt - 富途牛牛
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Ultragenyx Begins FDA Marketing Application for DTX401 Gene Therapy for GSD Type Ia - AInvest
Ultragenyx Begins FDA Application for DTX401 Gene Therapy - TipRanks
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Neuren Pharma, Anavex Life Sciences, Edison Pharma, Novartis, Ultragenyx Pharma, GW Pharma, Q-State - Barchart.com
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy By Investing.com - Investing.com Nigeria
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy - Investing.com
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy - MarketScreener
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa. - AInvest
Ultragenyx Initiates Rolling Submission of Biologics - GlobeNewswire
Ultragenyx Initiates Rolling Submission of Biologics License Application for DTX401 AAV Gene Therapy to Treat GSDIa - AInvest
64% Treatment Success: Ultragenyx's Gene Therapy DTX401 Advances FDA Review for Rare Disease GSDIa - Stock Titan
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome - MSN
Pomerantz LLP investigates Ultragenyx Pharmaceutical securities fraud claims. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
Will earnings trigger a reversal in Ultragenyx Pharmaceutical Inc.Trade Risk Report & Free High Return Stock Watch Alerts - Newser
Why Ultragenyx (RARE) Is Up 7.8% After Reporting Narrowed Losses and Higher Q2 Revenue - simplywall.st
Will Ultragenyx Pharmaceutical Inc. bounce back from current supportJuly 2025 Market Mood & Accurate Intraday Trade Tips - Newser
How high can Ultragenyx Pharmaceutical Inc. stock goEarnings Overview Report & Reliable Intraday Trade Plans - Newser
Price Clustering Detected in Ultragenyx Pharmaceutical Inc. StockWeekly Trade Summary & Safe Investment Capital Preservation Plans - sundaytimes.kr
Ultragenyx Pharmaceutical Inc. Shows Support at Fibonacci LevelWeekly Risk Summary & Community Verified Watchlist Alerts - metal.it
Navigating Legal Storms in Biotech: The Ultragenyx Case and Investor Caution - AInvest
Ultragenyx Pharmaceutical faces securities fraud investigation. - AInvest
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Trade Entry Summary & Verified Short-Term Plans - Newser
How sentiment analysis helps forecast Ultragenyx Pharmaceutical Inc.2025 Risk Factors & Safe Capital Allocation Plans - Newser
Long term hold vs stop loss in Ultragenyx Pharmaceutical Inc.July 2025 Trends & Fast Gaining Stock Strategy Reports - Newser
Is Ultragenyx Pharmaceutical Inc. the Top Chart Pick This WeekMarket Volume Summary & Free Weekly Watchlist of Top Performers - 선데이타임즈
What are analysts’ price targets for Ultragenyx Pharmaceutical Inc.July 2025 Action & Verified Chart Pattern Trade Signals - sundaytimes.kr
RSI Reset May Fuel Rebound in Ultragenyx Pharmaceutical Inc.Wall Street Watch & Free AI Powered Buy and Sell Recommendations - newsyoung.net
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - MSN
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersHigh Conviction Stock Long-Term Summary - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser
Ultragenyx's Q2 earnings exceed expectations, price target lowered to $128 by Canaccord. - AInvest
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights - AInvest
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyEquity Portfolio Outlook and Performance Summary - Newser
RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
FDA requests manufacturing changes for UX111 gene therapy - Sanfilippo Syndrome News
Ultragenyx Bets On Growth With Bullish Analyst Backing - Finimize
1.55%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):